Dr. Zufeng Guo

Department of Pharmacology and Molecular Sciences

Johns Hopkins University School of Medicine, USA

Research Associate

Email: [email protected], [email protected]

Qualifications

2010-present Ph.D., Johns Hopkins University School of Medicine, Baltimore, USA

2003-2010 Ph.D., Hong Kong University of Science and Technology, Hong Kong, China

2000-2003 M.S., Fuzhou University, Fuzhou, China

1996-2000 B.S., Fuzhou University, Fuzhou, China

Publications (Selected)

1. Ma, Y., Teng, Y., & Liu, J., et al. (2026). Systematic optimization of proteolysis-targeting chimeras for PIN1 enables selective degradation and antitumor activity in vivo. Pharmaceutics, 18(3), 288.
2. Wei, Y., Gao, Y., & Li, R., et al. (2026). High-throughput ligand discovery in living cells using the cellular protein stability enhancement assay. Acta Pharmaceutica Sinica B, 16(7), 4524–4538.
3. Xia, C., Cui, Y., & Wang, J., et al. (2026). Reduced maintenance DNA methylation thresholds enable sensitive reporter assays for UHRF1 and DNMT1 inhibition. Advanced Science, e19080.
4. Gao, Y., Ni, D., & Li, Y., et al. (2025). GLUTs-facilitated targeting BRD4 degradation in breast cancer through carbohydrate-conjugated PROTACs. Journal of Medicinal Chemistry.
5. Zhang, K., Zhu, Y., & Zhang, W., et al. (2025). LigDockTailor: Ligand-specific docking tool matching using multidimensional descriptors. Computational Biology and Chemistry, 108554.
6. He, J., Yu, H., & Song, K., et al. (2025). Rapavir, a novel inhibitor of sodium taurocholate cotransporting polypeptide, potently blocks hepatitis B virus entry. Signal Transduction and Targeted Therapy, 10(1), 130.
7. Tang, R., Luo, S., & Liu, H., et al. (2025). Circulating tumor microenvironment in metastasis. Cancer Research.
8. Peng, H., Guo, Z., & Wang, W. L., et al. (2025). Rapaprotin, an endopeptidase-activated proteasome inhibitor that induces 26S disassembly. Angewandte Chemie International Edition, e202500288.
9. Kotlyar, M., Guo, Z., & Rao, A. V. S., et al. (2025). Identification of rapaglutin E as an isoform-specific inhibitor of glucose transporter 1. ACS Chemical Biology.
10. Yu, H., Ren, J., & Deng, H., et al. (2025). Neuropilin-1 is a novel host factor modulating the entry of hepatitis B virus. Journal of Hepatology, 82(1), 37–50.
11. Ni, K. D., Fu, X., & Luo, Y., et al. (2024). Epoxy metabolites of linoleic acid promote the development of breast cancer via orchestrating PLEC/NFκB1/CXCL9-mediated tumor growth and metastasis. Cell Death & Disease, 15(12), 901.
12. Zheng, J., Zhang, W., & Ni, D., et al. (2024). Design, synthesis, and biological evaluation of 3-amino-pyrazine-2-carboxamide derivatives as novel FGFR inhibitors. ACS Medicinal Chemistry Letters, 15(11), 2019–2031.
13. Lv, L., Song, K., & Xiao, Y., et al. (2024). Design, synthesis and anticancer activity of β-carboline based pseudo-natural products by inhibiting AKT/mTOR signaling pathway. Bioorganic Chemistry, 151, 107648.
14. Song, K., Zhang, L., & Fu, X., et al. (2024). A rapid and simple non-radioactive assay for measuring uptake by solute carrier transporters. Frontiers in Pharmacology, 15, 1355507.
15. Wang, X., Yin, G., & Zhang, W., et al. (2023). Corrigendum: Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy. Frontiers in Pharmacology, 14, 1220144.
16. Zhao, S., He, Y., & Gao, F., et al. (2023). Rapid access to C2-quaternary 3-methyleneindolines via base-mediated post-Ugi Conia-ene cyclization. Chemical Communications, 59(21), 3099–3102.
17. Zheng, J., Zhang, W., & Li, L., et al. (2022). Signaling pathway and small-molecule drug discovery of FGFR: A comprehensive review. Frontiers in Chemistry, 10, 860985.
18. Wang, X., Yin, G., & Zhang, W., et al. (2021). Prostaglandin reductase 1 as a potential therapeutic target for cancer therapy. Frontiers in Pharmacology, 12, 717730.
19. Wang, Y., Peng, H., & Guo, Z., et al. (2021). Influence of stereochemistry on the activity of rapadocin, an isoform-specific inhibitor of the nucleoside transporter ENT1. Chemical Science, 12(34), 11484–11489.
20. Guo, Z., Peng, H., & Xie, Y. (2020). BET family protein degraders poised to join the senolytic arsenal. Signal Transduction and Targeted Therapy, 5(1), 88.
21. Liberti, M. V., Allen, A. E., & Ramesh, V., et al. (2020). Evolved resistance to partial GAPDH inhibition results in loss of the Warburg effect and in a different state of glycolysis. Journal of Biological Chemistry, 295(1), 111–124.

Profile Details
https://scholar.google.com/citations?user=p6QuBMAAAAAJ&hl=en
https://www.researchgate.net/profile/Zufeng-Guo

WOS ResearcherID: EXW-5114-2022